Rui Therapeutics completes tens of millions of RMB in Pre-A round financing, led by ShuiMuChunjin Capital.
On July 13th, 2023, Rui Therapeutics recently announced the completion of a Pre-A round of financing of tens of millions of RMB. This round of financing was led by ShuiMuChunjin Capital, with Zhejiang Fuju Investment participating in this round of investment.
This round of financing will be used for Rui Therapeutics to complete IND submissions, advance pipeline products, research initiated by researchers on existing R&D projects (IIT), and early-stage pipeline R&D.
Established in June 2021, Rui Therapeutics is a platform company focusing on the research and development of new drugs based on new-generation cells. The company was co-founded by returned overseas scientists and executives of multinational pharmaceutical companies, committed to innovation in core technologies with independent intellectual property rights. Rui Therapeutics has established three major platforms in the field of cell therapy: first, the CAR-NK platform; second, the single-base gene editing platform; third, the iPSC platform induced by small molecules. Focusing on inventive innovation, the company has established core technologies with its own intellectual property rights, such as CAR structure design technology for CAR-NK R&D, HTAS-RV™ viral delivery system, and CRA-NKTM taming technology. Currently, the company has laid out the most cutting-edge First-in-class pipeline products, covering the fields of tumors, autoimmune diseases, central nervous system diseases, and anti-aging, where clinical needs have not yet been met.
The company has established long-term cooperative partnerships with clinical centers such as Shanghai Changhai Hospital and the Affiliated Hospital of Jiangsu University. Early clinical IIT research data has shown the good efficacy and excellent safety of the company's CAR-NK cell drugs, with very high development potential and excellent commercial prospects in the future.
Dr. Qian Hao, co-founder and CEO of Rui Therapeutics, said that the success of a biopharmaceutical company lies in invention and creation, and the key is the pharmaceutical concept and clinical rhythm. Rui Therapeutics has established an R&D team led by returned overseas scientists and a CMC team led by executives of multinational pharmaceutical companies in the past two years. According to Dr. Qian Hao, the company has launched several clinical IIT trials of CAR-NK cell products, with the first pipeline product undergoing IIT clinical trials at Shanghai Changhai Hospital, showing excellent safety and tumor cell clearance effects, and is in the process of IND submission; two other pipeline products have passed ethical approval and are recruiting patients for related IIT clinical trials. Other pipeline-related experiments have also proven to have good safety and therapeutic effects through preclinical research. In the future, Rui Therapeutics will further strengthen the innovation of core technologies, the upgrade of pipeline products, the expansion of clinical indications, and international cooperation. We are very grateful for the trust and support of this round of investors to Rui Therapeutics. In the future, we will continue to leverage Rui Therapeutics’ strengths and advantages in cell therapy to create greater value in the field of innovative cell therapy.
An Yuming, General Manager of ShuiMuChunjin Capital, said that on January 30, 2022, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" jointly issued by the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Commerce, the National Health Commission, the Ministry of Emergency Management, the National Medical Insurance Administration, the National Medical Products Administration, and the National Administration of Traditional Chinese Medicine proposed: Focus on the development of immune cell therapy, stem cell therapy, etc. ShuiMuChunjin Capital has always focused on investment layout in the field of biopharmaceuticals, and has been paying attention to the development of the cell therapy field for many years, especially in the NK cell field. After several studies, it was found that NK cells are the most potential universal off-the-shelf cell therapy products. NK cells do not depend on MHC, have T cell-like killing ability, and do not express TCR-like receptors. They do not attack the host when infused into an allogeneic body and do not induce GvHD. The fastest products in the international CAR-NK cell therapy track have entered the clinical phase II research stage, led by the MD Anderson Cancer Center (Takeda Pharmaceutical) and Nkarta in the United States. Domestically, we most recognize the innovation of Rui Therapeutics’ underlying technology and the technical route of product development. The core team of entrepreneurs has been deeply involved in the cell therapy industry for many years. We are very confident in the future development of Rui Therapeutics and hope to participate in this innovative process through the collaborative empowerment of our organization.
[This article is published based on public information. If there are any objections, please contact (editor@zero2ipo.com.cn) Investment World for processing.
